GHK-Cu, KPV, BPC-157 and TB-500: a four-compound stack with no combination evidence, and four literatures in four different routes

What it is. The three-compound glow stack with a fourth added: GHK-Cu for skin, TB-500 and BPC-157 for repair, and KPV, a three-amino-acid fragment of the hormone alpha-MSH, added for inflammation and the gut.

Nothing has tested any combination of the four. The three-compound version has not been tested either. The combination ledger here is empty.

Each component's research used a route this stack does not. The copper peptide's human studies are creams. The thymosin work is eye drops and infusions. BPC-157's human record is two people. And KPV's animal studies deliver it orally, inside engineered particles and gels built to survive digestion and release it at inflamed tissue.

That last one is the sharpest mismatch on this site. KPV's results are as much about the delivery system as about the peptide.

Adding a fourth compound to an untested three multiplies what is unknown. No published analysis describes four peptides in one solution.

No indexed study has given these four compounds together, and none has given the three-compound version together either. The ledger for this record is empty, which is why the section below renders an empty state rather than a list.

Nothing ranks for the four-compound stack in search results either. The pages that rank are about KPV on its own, where a pharmacy chain leads and a primary study on how KPV is transported into colon cells sits fifth.

KPV is the C-terminal tripeptide of alpha-MSH, lysine-proline-valine, and its anti-inflammatory effect in the gut is real in animals. How it gets there is the point.

The peptide is carried into colon cells by PepT1, a transporter that is overexpressed in inflamed colonic epithelium, which is what makes the gut a target at all. A 2016 study showed the dependence directly: when administered to PepT1-KO mice, KPV did not trigger any of the inhibitory effect on tumorigenesis observed in WT mice. Remove the transporter and the effect disappears.

The studies that show benefit are therefore studies of delivery. One used a self-cross-linked hydrogel to stabilise the tripeptide, reporting that the KPV/SH-PGA hydrogel treatment prevented the colon shortening of TNBS-infused rats and decreased the colonic myeloperoxidase level. Another built a mucoadhesive gel for the mouth, where treatment with KPV@PPP_2%E hydrogel greatly improved the food intake and body weight recovery of rats with chemotherapy-induced oral mucositis. Others encapsulate it in hyaluronic-acid nanoparticles inside chitosan-alginate gels.

None of that is a subcutaneous injection of plain KPV. The engineering exists because a bare tripeptide does not survive the journey, and the results belong to the combination of peptide and carrier.

KPV's full record, including its two human entries, which are cell studies rather than people, is here: KPV.

Three compounds with no combination evidence is a gap. Four is the same gap with an extra unknown attached, and the arithmetic does not improve: each addition multiplies the number of interactions nobody has looked at, while adding no evidence of its own.

There is also a practical question nobody has answered publicly. Four peptides in one solution is a stability problem, and no published analysis describes what happens to these four together, or to their individual concentrations over the time a vial is used.

The three-compound version of this stack has its own page, with the same route argument at greater length: the glow stack.

No published dose exists for any combination of these four. Each component's studied doses sit on its own record with the study and the route that produced them, and in every case that route differs from injection.

Records: GHK-Cu, KPV, BPC-157 and TB-500.

Each compound's safety record belongs to its route. GHK-Cu has a long topical cosmetic history, which says nothing about injecting a copper-carrying peptide. Thymosin beta-4 was tolerated in eye and infusion studies. BPC-157's human safety record is the same two people as its efficacy record. KPV's safety data comes from rodents receiving it inside delivery vehicles.

For the four together there is nothing, and the ordinary uncertainties of an unregulated blend apply four times over.

Discussed for: skin, hair, gut inflammation and recovery at once, which is the appeal of a four-compound stack and also the reason to be careful: a protocol aimed at everything has no endpoint that could fail.

Studied in: people using creams, people with dry eye, two people given BPC-157, and rodents given KPV inside engineered carriers.

The unresolved questions start with whether any of the four reaches its target after subcutaneous injection, and for KPV specifically whether the PepT1-dependent mechanism that makes it work in the gut means anything at all when it is injected elsewhere.

GHK-Cu is a cosmetic ingredient sold in topical products, which is not an approval for injection. KPV, BPC-157 and TB-500 are unapproved and sold as research chemicals. A four-compound injectable blend is an approved product nowhere, and all of the injectables are prohibited in sport under the categories covering peptides and growth factors.

1. Citing KPV's gut results for an injection. Those studies delivered it orally inside carriers designed to reach the colon, and the effect depends on a transporter in colon cells.
2. Adding a compound to fix a gap in the evidence. A fourth untested component does not strengthen an untested three.
3. Reading a cosmetic ingredient's safety as an injectable's. GHK-Cu's record is topical.
4. Treating TB-500 and thymosin beta-4 as the same thing. The human evidence belongs to the protein, mostly as eye drops.
5. Assuming four peptides are stable in one vial. No published analysis says so.
6. Expecting a protocol aimed at everything to be testable. A stack for skin, gut and recovery at once has no endpoint that could fail.